Countdown to the biggest trade of my 25 yr career

Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.

Click here to see the surprising reason why

John Cox Biography and Net Worth

President & CEO of Dyne Therapeutics

John brings to Dyne extensive executive experience in the biotechnology industry across various operating roles, including rare disease commercialization. Mr. Cox was CEO of Bioverativ Inc., a rare disease spin-off from Biogen Inc., from 2017-2018, during which time the company grew to $1.1 billion in global sales and nearly 500 employees before being acquired by Sanofi S.A. Most recently, he served as CEO of Repertoire Immune Medicines and its predecessor from 2019 until 2022. Mr. Cox held various roles of increasing responsibility during a 14-year tenure at Biogen, including as executive vice president, global commercial & technical operations. Mr. Cox holds an MBA from the University of Michigan, an M.S. in cell biology from California State University and a B.S. in biology from Arizona State University.

What is John Cox's net worth?: The estimated net worth of John Cox is at least $226,960.00 as of September 4th, 2024. Mr. Cox owns 8,000 shares of Dyne Therapeutics stock worth more than $226,960 as of October 31st. This net worth estimate does not reflect any other investments that Mr. Cox may own. Learn More about John Cox's net worth.
How old is John Cox?: Mr. Cox is currently 61 years old. There are 7 older executives and no younger executives at Dyne Therapeutics. The oldest executive at Dyne Therapeutics is Dr. Oxana Beskrovnaya Ph.D., Chief Scientific Officer, who is 63 years old. Learn More on John Cox's age.
How do I contact John Cox?: The corporate mailing address for Mr. Cox and other Dyne Therapeutics executives is 1560 Trapelo Road, Waltham, MA 02451, United States. Dyne Therapeutics can also be reached via phone at 781-786-8230 and via email at [email protected]. Learn More on John Cox's contact information.
Has John Cox been buying or selling shares of Dyne Therapeutics?: John Cox has not been actively trading shares of Dyne Therapeutics in the last ninety days. Most recently, on Wednesday, September 4th, John Cox bought 32,000 shares of Dyne Therapeutics stock. The stock was acquired at an average cost of $33.04 per share, with a total value of $1,057,280.00. Following the completion of the transaction, the chief executive officer now directly owns 8,000 shares of the company's stock, valued at $264,320. Learn More on John Cox's trading history.
Who are Dyne Therapeutics' active insiders?: Dyne Therapeutics' insider roster includes Joshua Brumm (CEO), John Cox (President & CEO), Wildon Farwell (Insider), Susanna High (COO), Dirk Kersten (Director), and Richard Scalzo (Insider). Learn More on Dyne Therapeutics' active insiders.
Are insiders buying or selling shares of Dyne Therapeutics?: During the last year, Dyne Therapeutics insiders bought shares 2 times. They purchased a total of 1,746,285 shares worth more than $31,057,267.50. During the last year, insiders at the sold shares 50 times. They sold a total of 2,544,366 shares worth more than $62,196,431.71. The most recent insider tranaction occured on October, 16th when Director Dirk Kersten sold 23,671 shares worth more than $836,769.85. Insiders at Dyne Therapeutics own 20.8% of the company. Learn More about insider trades at Dyne Therapeutics.
Information on this page was last updated on 10/16/2024.

John Cox Insider Trading History at Dyne Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/4/2024	Buy	32,000	$33.04	$1,057,280.00	8,000

John Cox Buying and Selling Activity at Dyne Therapeutics

Dyne Therapeutics Company Overview

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $28.59

$28.22

$29.20

50 Day Range

MA: $35.34

$29.20

$46.53

2 Week Range

Now: $28.59

$6.66

$47.45

Volume

575,574 shs

Average Volume

1,504,424 shs

Market Capitalization

$2.87 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Countdown to the biggest trade of my 25 yr career

From Timothy Sykes | Ad